(Q38036690)

27 August 2017

title

Prostate cancer vaccines in clinical trials (English)

1 reference

27 August 2017

1 reference

David M Lubaroff

1

1 reference

27 August 2017

publication date

1 July 2012

1 reference

Expert Review of Vaccines

27 August 2017

published in

1 reference

27 August 2017

volume

11

1 reference

27 August 2017

issue

7

1 reference

27 August 2017

page(s)

857-868

1 reference

27 August 2017

cites work

Cancer statistics, 2012

1 reference

Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer

21 January 2018

1 reference

Abiraterone and increased survival in metastatic prostate cancer

21 January 2018

1 reference

Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer

21 January 2018

1 reference

Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer

21 January 2018

1 reference

Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial

21 January 2018

1 reference

Targeted therapies for prostate cancer against the prostate specific membrane antigen

21 January 2018

1 reference

Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination

21 January 2018

1 reference

Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial

21 January 2018

1 reference

STEAP, a prostate tumor antigen, is a target of human CD8+ T cells

21 January 2018

1 reference

Prophylactic vaccines for prevention of prostate cancer

21 January 2018

1 reference

Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes.

21 January 2018

1 reference

Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine

21 January 2018

1 reference

Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man.

21 January 2018

1 reference

Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients

21 January 2018

1 reference

Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors

21 January 2018

1 reference

Induction of CD8 T cells by vaccination with recombinant adenovirus expressing human papillomavirus type 16 E5 gene reduces tumor growth

21 January 2018

1 reference

Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors

21 January 2018

1 reference

DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer

21 January 2018

1 reference

Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer

21 January 2018

1 reference

Preclinical evaluation of a recombinant anti-prostate specific membrane antigen single-chain immunotoxin against prostate cancer

21 January 2018

1 reference

The next wave of recombinant and synthetic anticancer vaccines

21 January 2018

1 reference

Co-delivery of PSA and PSMA DNA vaccines with electroporation induces potent immune responses.

21 January 2018

1 reference

Immunization with recombinant DNA and modified vaccinia virus Ankara (MVA) vectors delivering PSCA and STEAP1 antigens inhibits prostate cancer progression.

21 January 2018

1 reference

Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine

21 January 2018

1 reference

DNA fusion gene vaccines induce cytotoxic T-cell attack on naturally processed peptides of human prostate-specific membrane antigen.

21 January 2018

1 reference

A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses

21 January 2018

1 reference

Anti-tumor immune response induced by dendritic cells transduced with truncated PSMA IRES 4-1BBL recombinant adenoviruses

21 January 2018

1 reference

In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen

21 January 2018

1 reference

A recombinant vaccinia virus expressing human prostate‐specific antigen (PSA): Safety and immunogenicity in a non‐human primate

21 January 2018

1 reference

Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine

21 January 2018

1 reference

Tumor immunotherapy using adenovirus vaccines in combination with intratumoral doses of CpG ODN

21 January 2018

1 reference

Restoration of antitumor immunity through selective inhibition of myeloid derived suppressor cells by anticancer therapies

21 January 2018

1 reference

Sipuleucel-T: Prototype for development of anti-tumor vaccines

21 January 2018

1 reference

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

Listening to Provenge--what a costly cancer treatment says about future Medicare policy

21 January 2018

1 reference

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer

21 January 2018

1 reference

Therapeutic Cancer Vaccines in Prostate Cancer: The Paradox of Improved Survival Without Changes in Time to Progression

21 January 2018

1 reference

Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy

21 January 2018

1 reference

A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer

21 January 2018

1 reference

Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer

21 January 2018

1 reference

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

21 January 2018

1 reference

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

21 January 2018

1 reference

Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer

21 January 2018

1 reference

Clinical protocol: phase I study of an adenovirus/prostate-specific antigen vaccine in men with metastatic prostate cancer

21 January 2018

1 reference

Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results.

21 January 2018

1 reference

Mechanisms of immune evasion by tumors

21 January 2018

1 reference

T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer

21 January 2018

1 reference

Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen

21 January 2018

1 reference

Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer

21 January 2018

1 reference

Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells

21 January 2018

1 reference

Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma

21 January 2018

1 reference

HER-2/neu as a target for cancer vaccines

21 January 2018

1 reference

A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer

21 January 2018

1 reference

Immunological evaluation of personalized peptide vaccination monotherapy in patients with castration-resistant prostate cancer.

21 January 2018

1 reference

A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors

21 January 2018

1 reference

Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination

21 January 2018

1 reference

Myeloid dendritic cell precursors generated from bone marrow suppress T cell responses via cell contact and nitric oxide production in vitro.

21 January 2018

1 reference

L-428 nodular sclerosing Hodgkin's cell secretes a unique transforming growth factor-beta active at physiologic pH.

21 January 2018

1 reference

Immunoregulatory effects of L-arginine and therapeutical implications

21 January 2018

1 reference

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

21 January 2018

1 reference

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

21 January 2018

1 reference

Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation

21 January 2018

1 reference

The immunobiology of cancer immunosurveillance and immunoediting

21 January 2018

1 reference

Therapeutic vaccination for cancer immunotherapy: antigen selection and clinical responses.

21 January 2018

1 reference

Assessing oncologic benefit in clinical trials of immunotherapy agents

21 January 2018

1 reference

Augmentation of T Cell Levels and Responses Induced by Androgen Deprivation

21 January 2018

1 reference

Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma

21 January 2018

1 reference

A methodological framework to enhance the clinical success of cancer immunotherapy

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERV.12.54

1 reference

27 August 2017

1 reference